Cizzle Biotechnology Holdings Plc

Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.